Jackson Acquisition II Receives NYSE Noncompliance Notice

The latest update is out from Jackson Acquisition Co. II Class A ( (JACS) ).

On February 10, 2026, Jackson Acquisition Company II disclosed that it had received a noncompliance notice from the New York Stock Exchange dated February 6, 2026, for failing to maintain the required minimum of 300 public stockholders. The company has 45 days from receipt of the notice to submit a business plan showing how it will regain compliance with the NYSE listing rule within 18 months, a timetable that will be reviewed and approved at the exchange’s discretion.

The notice does not immediately affect the listing or trading of Jackson Acquisition Company II’s securities, which are expected to remain on the NYSE during the 18‑month cure period if the plan is accepted and other listing standards are met. However, failure to win NYSE approval or to execute on the remediation plan could trigger suspension and delisting procedures, raising potential risks for investors and for the company’s ability to execute its healthcare-focused acquisition strategy.

More about Jackson Acquisition Co. II Class A

Jackson Acquisition Company II is a special purpose acquisition company formed to effect a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While it can target any sector or geography, it is primarily focused on identifying healthcare services and healthcare technology companies or others centered on the healthcare industry.

As a SPAC, the company raises capital in public markets to later combine with a private target, offering an alternative route to listing for healthcare-focused businesses. Its strategy positions it within the competitive market for healthcare-related dealmaking, where scale, investor base and exchange listing status are key factors for attracting suitable acquisition targets.

On February 10, 2026, Jackson Acquisition Company II disclosed that it had received a noncompliance notice from the New York Stock Exchange dated February 6, 2026, for failing to maintain the required minimum of 300 public stockholders. The company has 45 days from receipt of the notice to submit a business plan showing how it will regain compliance with the NYSE listing rule within 18 months, a timetable that will be reviewed and approved at the exchange’s discretion.

The notice does not immediately affect the listing or trading of Jackson Acquisition Company II’s securities, which are expected to remain on the NYSE during the 18‑month cure period if the plan is accepted and other listing standards are met. However, failure to win NYSE approval or to execute on the remediation plan could trigger suspension and delisting procedures, raising potential risks for investors and for the company’s ability to execute its healthcare-focused acquisition strategy.

Average Trading Volume: 56,162

Technical Sentiment Signal: Strong Buy

Current Market Cap: $280.6M

For a thorough assessment of JACS stock, go to TipRanks’ Stock Analysis page.